Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up.

Bulletin of experimental biology and medicine2011PMID: 22451889

Randomized Controlled TrialEpitalon

Plain Language Summary

In a 15-year follow-up study, elderly coronary patients who received six courses of epithalamin over three years showed decelerated cardiovascular aging, preserved physical endurance, normalized melatonin circadian rhythm, and improved carbohydrate and lipid metabolism. The epithalamin-treated group also had significantly lower mortality compared to the control group receiving only standard therapy.

Abstract

The paper presents the results of randomized comparative study of the efficiency of peptide geroprotector from the pituitary gland in elderly patients with rapidly aging cardiovascular system. Over three years 39 coronary patients received, in addition to basic therapy, regular courses of epithalamin (peptide drug), while 40 coronary patients (control group) received basic therapy alone. Long-term treatment with epithalamin (6 courses over 3 years) decelerated aging of the cardiovascular system, prevented age-associated impairment of physical endurance, normalized circadian rhythm of melatonin production and carbohydrate and lipid metabolism. A significantly lower mortality in the group of patients treated with epithalamin in parallel with basic therapy also indicated a geroprotective effect of the peptide preparation from the pineal gland.

Authors

Korkushko, O V; Khavinson, V Kh; Shatilo, V B; Antonyk-Sheglova, I A